These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

663 related articles for article (PubMed ID: 27184586)

  • 41. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials.
    Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW;
    JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optical coherence tomography tissue coverage and characterization at six months after implantation of bioresorbable scaffolds versus conventional everolimus eluting stents in the ISAR-Absorb MI trial.
    Rai H; Alfonso F; Maeng M; Bradaric C; Wiebe J; Cuesta J; Christiansen EH; Cassese S; Hoppmann P; Colleran R; Harzer F; Bresha J; Nano N; Schneider S; Laugwitz KL; Joner M; Kastrati A; Byrne RA
    Int J Cardiovasc Imaging; 2021 Oct; 37(10):2815-2826. PubMed ID: 34420177
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Is quantitative coronary angiography reliable in assessing the lumen gain after treatment with the everolimus-eluting bioresorbable polylactide scaffold?
    Sotomi Y; Onuma Y; Suwannasom P; Tateishi H; Tenekecioglu E; Zeng Y; Cavalcante R; Jonker H; Dijkstra J; Foin N; Koon JN; Collet C; de Winter RJ; Wykrzykowska JJ; Stone GW; Popma JJ; Kozuma K; Tanabe K; Serruys PW; Kimura T
    EuroIntervention; 2016 Oct; 12(8):e998-e1008. PubMed ID: 27721215
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Post-dilatation after implantation of bioresorbable everolimus- and novolimus-eluting scaffolds: an observational optical coherence tomography study of acute mechanical effects.
    Blachutzik F; Boeder N; Wiebe J; Mattesini A; Dörr O; Most A; Bauer T; Röther J; Tröbs M; Schlundt C; Achenbach S; Hamm CW; Nef HM
    Clin Res Cardiol; 2017 Apr; 106(4):271-279. PubMed ID: 27757522
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of coronary bifurcation lesions with the Absorb bioresorbable vascular scaffold in combination with the Tryton dedicated coronary bifurcation stent: evaluation using two- and three-dimensional optical coherence tomography.
    Grundeken MJ; Hassell ME; Kraak RP; de Bruin DM; Koch KT; Henriques JP; van Leeuwen TG; Tijssen JG; Piek JJ; de Winter RJ; Wykrzykowska JJ
    EuroIntervention; 2015 Dec; 11(8):877-84. PubMed ID: 25169592
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dedicated bifurcation stents or regular drug eluting stents in distal left main stenosis: A retrospective study.
    Kern A; Gil RJ; Bojko K; Rzeszowski B; Bednarski K; Górny J; Bil J
    Cardiol J; 2018; 25(2):188-195. PubMed ID: 28714525
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and efficacy profile of bioresorbable-polylactide-polymer-biolimus-A9-eluting stents versus durable-polymer-everolimus- and zotarolimus-eluting stents in patients with acute coronary syndrome.
    Jaguszewski M; Dörig M; Frangieh AH; Ghadri JR; Cammann VL; Diekmann J; Napp LC; D'Ascenzo F; Imori Y; Obeid S; Maier W; Lüscher TF; Templin C
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):E173-E182. PubMed ID: 27377554
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: Clinical outcomes from randomized controlled trials.
    Rizik DG; Hermiller JB; Kereiakes DJ
    Catheter Cardiovasc Interv; 2016 Nov; 88(S1):21-30. PubMed ID: 27797464
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Analysis of left main coronary artery bifurcation lesions treated with biolimus-eluting DEVAX AXXESS plus nitinol self-expanding stent: intravascular ultrasound results of the AXXENT trial.
    Hasegawa T; Ako J; Koo BK; Miyazawa A; Sakurai R; Chang H; Dens J; Verheye S; Grube E; Honda Y; Fitzgerald PJ
    Catheter Cardiovasc Interv; 2009 Jan; 73(1):34-41. PubMed ID: 19089934
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preliminary Report of Clinical Outcomes After Single Crossover Bioresorbable Scaffold Implantation Without Routine Side Branch Strut Dilation.
    Tanaka A; Jabbour RJ; Kawamoto H; Mangieri A; Pagnesi M; Montalto C; Chieffo A; Carlino M; Montorfano M; Latib A; Colombo A
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):865-870. PubMed ID: 27219102
    [TBL] [Abstract][Full Text] [Related]  

  • 51. One-year head to head comparison of the neointimal response between sirolimus eluting stent with reservoir technology and everolimus eluting stent: an optical coherence tomography study.
    Shiratori Y; Brugaletta S; Alvarez-Contreras L; Azpeitia Y; Ospino N; Gaido S; Delahanty A; Santos A; Martin-Yuste V; Masotti M; Serruys PW; Windecker S; Sabaté M
    Catheter Cardiovasc Interv; 2013 Oct; 82(4):E428-36. PubMed ID: 23441068
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outcome After Long-segment Stenting With Everolimus-eluting Bioresorbable Scaffolds Focusing on the Concept of Overlapping Implantation.
    Wiebe J; Dörr O; Liebetrau C; Bauer T; Wilkens E; Ilstad H; Boeder N; Elsässer A; Möllmann H; Hamm CW; Nef HM
    Rev Esp Cardiol (Engl Ed); 2016 Dec; 69(12):1144-1151. PubMed ID: 28134094
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analysis of bifurcation lesions treated with novel drug-eluting dedicated bifurcation stent system: intravascular ultrasound results of the AXXESS PLUS trial.
    Miyazawa A; Ako J; Hassan A; Hasegawa T; Abizaid A; Verheye S; McClean D; Neumann FJ; Grube E; Honda Y; Fitzgerald PJ
    Catheter Cardiovasc Interv; 2007 Dec; 70(7):952-7. PubMed ID: 18044777
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 9-month clinical, angiographic, and intravascular ultrasound results of a prospective evaluation of the Axxess self-expanding biolimus A9-eluting stent in coronary bifurcation lesions: the DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) study.
    Verheye S; Agostoni P; Dubois CL; Dens J; Ormiston J; Worthley S; Trauthen B; Hasegawa T; Koo BK; Fitzgerald PJ; Mehran R; Lansky AJ
    J Am Coll Cardiol; 2009 Mar; 53(12):1031-9. PubMed ID: 19298915
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optical coherence tomography guidance for percutaneous coronary intervention with bioresorbable scaffolds.
    Caiazzo G; Longo G; Giavarini A; Kilic ID; Fabris E; Serdoz R; Mattesini A; Foin N; Secco GG; De Rosa S; Indolfi C; Di Mario C
    Int J Cardiol; 2016 Oct; 221():352-8. PubMed ID: 27404705
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Angiographic and Midterm Outcomes of Bioresorbable Vascular Scaffold for Coronary Bifurcation Lesions.
    Paradies V; Vlachojannis GJ; Royaards KJ; Wassing J; van der Ent M; Smits PC
    Am J Cardiol; 2018 Dec; 122(12):2035-2042. PubMed ID: 30360886
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real-World Bioresorbable Vascular Scaffold Experience Compared With Second-Generation Metallic Drug-Eluting Stents in Complex Coronary Lesions.
    Okamoto N; Ueda H; Yoshimura T; Chamaria S; Bhatheja S; Vengrenyuk Y; Rabiei S; Barrientos Y; Kapur V; Barman N; Sweeny J; Baber U; Mehran R; Sharma SK; Kini AS
    J Invasive Cardiol; 2018 Jul; 30(7):251-255. PubMed ID: 29656280
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A true bifurcational stenosis treated with a bioresorbable vascular scaffold and a drug-eluting metallic stent: Degradable meets durable.
    Wiebe J; Hamm C; Nef H
    Catheter Cardiovasc Interv; 2015 Jun; 85(7):1184-8. PubMed ID: 25581885
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: six-month angiographic and 12-month clinical results of the drug-eluting balloon in bifurcations trial.
    Stella PR; Belkacemi A; Dubois C; Nathoe H; Dens J; Naber C; Adriaenssens T; van Belle E; Doevendans P; Agostoni P
    Catheter Cardiovasc Interv; 2012 Dec; 80(7):1138-46. PubMed ID: 22422607
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of a fully bioresorbable vascular scaffold in patients with coronary artery disease: design of and rationale for the ABSORB III randomized trial.
    Kereiakes DJ; Ellis SG; Popma JJ; Fitzgerald PJ; Samady H; Jones-McMeans J; Zhang Z; Cheong WF; Su X; Ben-Yehuda O; Stone GW
    Am Heart J; 2015 Oct; 170(4):641-651.e3. PubMed ID: 26386787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.